Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Novavax ( (NVAX) ) has provided an update.
On August 20, 2025, Novavax announced it had entered into agreements to issue $225 million in 4.625% Convertible Senior Notes due 2031, replacing existing 5.00% Convertible Senior Notes due 2027 and raising new capital. This refinancing extends the maturity of most of its existing debt, improving the company’s capital structure and potentially impacting the market price of its stock and notes. The transactions are expected to close on or about August 27, 2025, with the company planning to use the proceeds for general corporate purposes.
The most recent analyst rating on (NVAX) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.
Spark’s Take on NVAX Stock
According to Spark, TipRanks’ AI Analyst, NVAX is a Neutral.
Novavax’s overall stock score is driven by positive technical indicators and promising corporate events, offset by financial instability and valuation concerns. The earnings call provided a positive outlook, but financial challenges remain a significant risk.
To see Spark’s full report on NVAX stock, click here.
More about Novavax
Novavax, Inc. is a biotechnology company focused on developing vaccines to address some of the world’s most pressing health challenges. Utilizing its scientific expertise and proven technology platform, which includes protein-based nanoparticles and the Matrix-M adjuvant, Novavax aims to optimize existing partnerships and expand its portfolio in infectious diseases and beyond.
Average Trading Volume: 6,275,647
Technical Sentiment Signal: Hold
Current Market Cap: $1.55B
For detailed information about NVAX stock, go to TipRanks’ Stock Analysis page.